EBI2 receptor as a new myelin repair therapy in multiple sclerosis.
2022/47/D/NZ3/02613
Keywords
Descriptors
- NZ3_006: Neurobiologia komórkowa
- NZ3_005: Neurobiologia molekularna
- NZ4_007: Neurofizjologia
Panel
NZ3 – Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology
Host institution
Gdański Uniwersytet Medyczny, Wydział Lekarski
Voivodeship: pomorskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 3
Call
SONATA 18 – announced on 2022-07-15
- Amount awarded
- 1 707 496 PLN
- Project start date
- 2023-12-01
- Project end date
- 2026-11-30
- Project duration
- 36 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Accelerated remyelination and immune modulation by the EBI2 agonist 7α,25-dihydroxycholesterol analogue in the cuprizone model
- Authors:
- Klaudia Konieczna-Wolska, Fionä Caratis, Mikołaj Opiełka, Karol Biernacki, Krzysztof Urbanowicz, Joanna Klimaszewska, Piotr Pobiarzyn, Oliwier Krajewski, Sebastian Demkowicz, Ryszard T. Smoleński, Bartosz Karaszewski, Klaus Seuwen, Aleksandra Rutkowska
- Academic press:
- Biomedicine & Pharmacotherapy (year: 2024, volume: 181, pages: 117653), Publisher: Elsevier
- Status:
- Published
- DOI:
- 10.1016/j.biopha.2024.117653 – link to the publication